Association of the Fibrosis-4 Index With Indices of Atherosclerosis in Patients With Type 2 Diabetes: An Exploratory Subanalysis of a Prospective Observational Cohort Study.
Аннотация
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by insulin resistance and metabolic syndrome, with type 2 diabetes mellitus (T2DM) as a major risk factor. Additionally, MASLD has been linked to liver fibrosis, which is associated with increased cardiovascular risk. Although noninvasive liver fibrosis markers are widely used, the association of these markers with atherosclerosis and continuous glucose monitoring (CGM) indices in T2DM remains unclear. We aimed to investigate the associations of the fibrosis-4 (FIB-4) index with atherosclerosis and CGM indices in patients with T2DM.
METHODS
This study was an exploratory subanalysis of a prospective observational cohort. Among 999 outpatients with T2DM who underwent baseline CGM, 887 patients (excluding heavy alcohol consumers) were analyzed. FIB-4, a noninvasive marker of liver fibrosis, was calculated. Associations of FIB-4 with carotid ultrasound, vascular wave velocity tests, and CGM indices were explored.
RESULTS
After adjusting for disease duration, body mass index (BMI), glycated hemoglobin (HbA1c), gamma-glutamyl transferase, and complications, FIB-4 severity category showed significant associations with mean intima-media thickness (IMT), common carotid artery (CCA) maximum IMT, and brachial-ankle pulse wave velocity in ordinal logistic analyses. Consistent with the ordinal logistic analyses, FIB-4 was independently associated with mean IMT in multivariable linear regression. Among the CGM indices, FIB-4 was positively associated with both mean glucose and the standard deviation (SD) of mean glucose. Moreover, FIB-4 was negatively associated with time in range (TIR) and positively with time above range (TAR).
CONCLUSIONS
In Japanese patients with T2DM, FIB-4 is associated with carotid thickening and arterial stiffness. Moreover, FIB-4 correlates with the duration of hyperglycemia, suggesting that liver fibrosis may be linked to atherosclerosis through mechanisms involving poor glycemic control. Assessment of liver fibrosis in T2DM is imperative, necessitating monitoring of atherosclerosis and cardiovascular diseases (CVDs) in cases of suspected advanced liver fibrosis.
TRIAL REGISTRATION: The study has been registered (UMIN000032325) in the University Hospital Medical Information Network Clinical Trials Registry, a nonprofit organization in Japan that meets the requirements of the International Committee of Medical Journal Editors.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.